Tirzepatide Dose Response: Weight Loss at Each Dose
Tirzepatide
22.5%
Mean body weight reduction at 72 weeks with tirzepatide 15 mg in the SURMOUNT-1 trial, the highest dose tested for obesity.
Jastreboff et al., NEJM, 2022
Jastreboff et al., NEJM, 2022
View as imageTirzepatide is the first dual GIP/GLP-1 receptor agonist approved for both type 2 diabetes (as Mounjaro) and weight management (as Zepbound). Unlike single-target GLP-1 drugs, tirzepatide activates two incretin receptors simultaneously, and it was tested at three dose levels: 5 mg, 10 mg, and 15 mg weekly.[1] The dose-response data from the SURMOUNT trial program shows a clear relationship between dose and weight loss, but the curve is not linear. The jump from 5 mg to 10 mg is large. The jump from 10 mg to 15 mg is much smaller. Understanding this pattern matters for clinical decision-making about how tirzepatide's dual mechanism differs from GLP-1 agonists and how dose escalation should be managed.
Key Takeaways
- SURMOUNT-1 showed mean weight loss of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) versus 3.1% for placebo at 72 weeks in 2,539 adults with obesity (Jastreboff et al., NEJM, 2022)
- 91% of participants on 15 mg lost at least 5% of their body weight; 57% lost at least 20%; and 36% lost at least 25%
- The largest dose-response increment is from 5 mg to 10 mg (5.4 percentage points); the 10 mg to 15 mg increment is only 1.1 percentage points
- SURMOUNT-2 in patients with type 2 diabetes showed lower but still significant weight loss: 12.8% (10 mg) and 14.7% (15 mg) at 72 weeks (Garvey et al., 2023)
- SURMOUNT-4 demonstrated that stopping tirzepatide 15 mg after 36 weeks led to 14% weight regain over the next 52 weeks, while continuing treatment maintained weight loss (Aronne et al., 2024)
- Gastrointestinal side effects (nausea, diarrhea, constipation) increase with dose but are mostly mild to moderate and concentrated during the dose escalation period
SURMOUNT-1: the definitive dose-response data
SURMOUNT-1 is the pivotal trial for tirzepatide's dose-response relationship in obesity. Published by Jastreboff and colleagues in the New England Journal of Medicine in 2022, it randomized 2,539 adults with a BMI of 30 or higher (or 27 with at least one weight-related comorbidity) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo, administered weekly by subcutaneous injection for 72 weeks.[1] Participants did not have diabetes.
The mean weight loss results defined the dose-response curve:
| Dose | Mean weight loss | Achieving 5%+ loss | Achieving 10%+ loss | Achieving 20%+ loss |
|---|---|---|---|---|
| 5 mg | 16.0% | 85% | 69% | 32% |
| 10 mg | 21.4% | 89% | 82% | 50% |
| 15 mg | 22.5% | 91% | 86% | 57% |
| Placebo | 3.1% | 35% | 14% | 3% |
The pattern reveals that the dose-response curve is steepest between 5 mg and 10 mg. Moving from 5 mg to 10 mg adds 5.4 percentage points of weight loss (from 16.0% to 21.4%). Moving from 10 mg to 15 mg adds only 1.1 percentage points (from 21.4% to 22.5%).[1]
This plateau effect at the highest dose has clinical implications. For many patients, 10 mg may deliver most of the achievable weight loss benefit. The additional 1.1 percentage points from escalating to 15 mg must be weighed against potentially higher rates of gastrointestinal side effects at the top dose.
However, looking at the categorical outcomes tells a slightly different story. The proportion of patients achieving 20% or greater weight loss increases from 50% at 10 mg to 57% at 15 mg. For patients targeting a specific threshold, that 7-percentage-point increase in the probability of reaching 20% loss may be clinically meaningful even though the mean difference is modest.
SURMOUNT-2: dose response in type 2 diabetes
SURMOUNT-2, published by Garvey and colleagues in 2023, tested tirzepatide 10 mg and 15 mg (not 5 mg) against placebo in 938 adults who had both obesity and type 2 diabetes.[3]
Weight loss in this population was lower than in SURMOUNT-1: 12.8% with 10 mg and 14.7% with 15 mg, compared to 3.2% with placebo at 72 weeks. The dose-response increment between 10 mg and 15 mg was larger in this trial (1.9 percentage points) than in SURMOUNT-1 (1.1 percentage points), though the absolute weight loss was lower.
The reduced weight loss in type 2 diabetes is a consistent finding across GLP-1 receptor agonist trials. Patients with diabetes tend to lose less weight than non-diabetic patients on the same drug at the same dose. The reasons likely include insulin resistance-related metabolic differences, concomitant medications that promote weight gain (insulin, sulfonylureas), and potentially different central appetite regulation in the diabetic state.
For the dose-response question specifically, SURMOUNT-2 suggests that 15 mg may provide more incremental benefit in diabetic patients than in non-diabetic patients. The difference between 10 mg and 15 mg was 1.9 percentage points for weight loss and the HbA1c reduction was also numerically greater at 15 mg.[3]
SURMOUNT-3 and SURMOUNT-4: dose and maintenance
SURMOUNT-3 tested a different approach. Wadden and colleagues enrolled participants who first completed a 12-week intensive lifestyle intervention (diet, exercise, behavioral counseling), achieving an average 6.9% weight loss before randomization. Participants then received tirzepatide (escalated to maximum tolerated dose up to 15 mg) or placebo for 72 weeks.[7]
Starting from the post-lifestyle-intervention baseline, tirzepatide produced an additional 18.4% weight loss versus 2.5% regain with placebo. Total weight loss from original baseline was 26.6% with tirzepatide. This trial did not isolate individual dose effects since participants escalated to maximum tolerated dose, but it demonstrated that higher doses after lifestyle intervention produce additive benefit.
SURMOUNT-4 addressed the question of what happens when tirzepatide is stopped. After an open-label lead-in period on tirzepatide (maximum tolerated dose, up to 15 mg) for 36 weeks, participants who had lost weight were randomized to either continue tirzepatide or switch to placebo for 52 weeks.[2]
Patients who continued tirzepatide maintained their weight loss and lost an additional 5.5%. Patients switched to placebo regained 14.0% of their body weight over the 52-week withdrawal period, though they remained below their original baseline. This demonstrates that the dose-dependent weight loss from tirzepatide requires ongoing treatment. Discontinuation leads to substantial regain, regardless of the dose that produced the initial loss.
Why the curve flattens at higher doses
The diminishing marginal return from 10 mg to 15 mg reflects biological ceiling effects in multiple pathways.
Appetite suppression has limits. Tirzepatide reduces food intake by approximately 25-30% at therapeutic doses through central appetite circuits and peripheral satiety signals.[4] Heise and colleagues showed that tirzepatide reduces appetite, energy intake, and preference for high-fat foods. At some dose, further receptor activation cannot suppress appetite further without intolerable nausea.
Gastric emptying delay reaches a plateau. GLP-1 receptor activation slows stomach emptying, contributing to postprandial satiety. Beyond a certain level of slowing, additional receptor stimulation does not meaningfully increase the delay.
Metabolic adaptation occurs. As patients lose weight, resting energy expenditure decreases proportionally. A person who has lost 20% of their body weight burns fewer calories at rest than they did at their starting weight. This metabolic slowdown partially offsets the energy deficit created by reduced food intake at any dose, creating a natural ceiling on achievable weight loss that higher receptor agonism cannot fully overcome.
The dose-response curve also flattens because some patients are already near their biologically achievable weight loss at 10 mg. For these responders, additional drug cannot overcome the body's homeostatic defense of remaining fat mass. The patients who gain the most from 15 mg versus 10 mg are likely those who have not yet reached their individual plateau.[1]
Side effects across doses
The gastrointestinal side effect profile follows a dose-response of its own. In SURMOUNT-1, nausea occurred in 24.6% of the 5 mg group, 33.3% of the 10 mg group, and 31.0% of the 15 mg group. Diarrhea occurred in 18.7%, 21.2%, and 23.0%, respectively. Constipation affected 12.0%, 12.1%, and 11.7%.[1]
The nausea rates plateau between 10 mg and 15 mg, possibly because the dose escalation protocol (gradual titration over 20 weeks) allows GI adaptation. Most GI side effects occurred during the dose escalation period and decreased with continued treatment. They were mostly rated as mild to moderate in severity.
Serious adverse events were low across all dose groups (5-7%) and similar to placebo. Discontinuation due to adverse events was 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg), compared to 2.6% for placebo. The 10 mg group had a slightly higher discontinuation rate than 15 mg, which may reflect random variation in a relatively small number of events rather than a true dose-response relationship for discontinuation.
Clinical dose selection: what the data supports
The Mounjaro and Zepbound prescribing information recommends starting at 2.5 mg (a sub-therapeutic dose used only for GI tolerability) and escalating by 2.5 mg every 4 weeks to the maintenance dose. The target maintenance dose can be 5 mg, 10 mg, or 15 mg, depending on individual response and tolerability.
The dose-response data from SURMOUNT-1 through SURMOUNT-4 supports several conclusions:
Most of the weight loss benefit is captured at 10 mg. The mean difference between 10 mg and 15 mg was 1.1 percentage points in non-diabetic patients. For patients who respond well to 10 mg and tolerate it, escalation to 15 mg produces a modest incremental benefit.
The 5 mg dose is not a placeholder. At 16.0% mean weight loss, tirzepatide 5 mg is already more effective than the maximum approved dose of semaglutide (2.4 mg, which produces approximately 15-17% weight loss). Patients who cannot tolerate higher doses still receive substantial benefit.[5]
In type 2 diabetes, 15 mg may provide more incremental benefit. The gap between 10 mg and 15 mg was larger in SURMOUNT-2 (1.9 points) than SURMOUNT-1 (1.1 points), suggesting that diabetic patients may benefit more from dose escalation.
Weight maintenance requires continued dosing. SURMOUNT-4 showed that stopping tirzepatide leads to significant weight regain regardless of dose. The dose question is therefore not just "what dose produces the most loss" but "what dose produces an acceptable result that the patient can maintain indefinitely." Cost, insurance coverage, and supply constraints may also factor into dose selection for long-term maintenance.[2]
The Bottom Line
Tirzepatide demonstrates a clear dose-response relationship for weight loss: 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg over 72 weeks in the SURMOUNT-1 trial. The curve steepens between 5 mg and 10 mg (5.4 percentage points) and flattens between 10 mg and 15 mg (1.1 percentage points), reflecting biological ceiling effects in appetite suppression, gastric emptying, and metabolic adaptation. In type 2 diabetes, the dose-response increment at 15 mg is somewhat larger. SURMOUNT-4 confirms that ongoing treatment is required to maintain weight loss at any dose. Clinical dose selection should balance the additional weight loss from higher doses against gastrointestinal tolerability and the diminishing marginal return above 10 mg.